1Alm A, Grierson I, Shields MB (2008) Side effects associated with prostaglandin analog therapy. Surv Ophthalmol.53(6 suppl): S93–S105.

2Calladine D (2007) Severe darkening of a facial skin graft from latanoprost. Arch Ophthalmol. 125:1427–1428.

3Wand M, Ritch R, I EK Jr, et al. (2001) Latanoprost and periocular skin color changes. Arch Ophthalmol. 119:614–615.

4Herndon LW, Williams RD, Wand M, et al. (2003) Increased periocular pigmentation with ocular hypotensive lipid use in African Americans. Am J Ophthalmol. 135:713–715.

5Sharpe ED, Reynolds AC, Skuta GL, et al. (2007) The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy. Curr Eye Res. 32:1037–1043.

6Tan J, Berke S. (2013) Latanoprost-induced prostaglandin-associated periorbitopathy. Optom Vis Sci. 90:e245–e247; discussion 1029.

7Sakata R, Shirato S, Miyata K, et al. (2014) Incidence of deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy with a latanoprost ophthalmic solution. Eye (Lond).28:1446–1451.

8Nakakura S, Yamamoto M, Terao E, et al. (2014) Prostaglandin associated periorbitopathy in latanoprost users. Clin Ophthalmol. 9:51–56.

9Lin M, Schmutz M, Mosaed S. (2017) Latanoprost-induced skin depigmentation. J Glaucoma 26:e246-e248.

10Arnalich-Montien F, Lara-Medina J, Munoz-Negrete FJ, Rebolleda G. (2004) The use of Xalacom and deterioration in cases of vitiligo. Is there a causal relationship? Arch Soc Esp Oftalmol. 79:315-316.

11Galloway GD, Eke T, Broadway DC. (2005) Periocular Cutaneous Pigmentary Changes Associated with Bimatoprost Use. Arch Ophthalmol 123:1609-10.

12Scott G, Jacobs S, Leopardi S, Anthony FA, Learn D, Malaviya R, Pentland A. (2005) Effects of PGF2alpha on human melanocytes and regulation of the FP receptor by ultraviolet radiation. Exp Cell Res 304, 407–416.

13Kapur R, Osmanovic S, Toyran S, et al. (2005) Bimatoprost-induced periocular skin hyperpigmentation: histopathological study. Arch Ophthalmol. 123:1541–1546.

14Grierson I, Jonsson M, Cracknell K. (2004) Latanoprost and pigmentation. Jpn J Ophthalmol. 48:602–612.

15Anbar TS, El-Ammawi TS, Abdel-Rahman AT, Hanna MR (2015) The effect oflatanoprost on vitiligo: A preliminary comparative study. Int J Dermatol 54:587-93.

16Rathod DJ, Shuttleworth GN (2007) Anterior uveitis, poliosis, and skin hypopigmentation associated with topical chloramphenicol allergy following ptosis surgery. Ophthal Plast Reconstr Surg 23: 318-319.

17Aleem A (2009) Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia. Hematol Oncol Stem Cell Ther 2:358-361.

18Tsao AS, Kantarjian H, Cortes J, O’Brien S, Talpaz M (2003) Imatinib mesylate causes hypopigmentation in the skin. Cancer. 98:2483-2487.

19Pradeep Balasubramanian, Soumya Jagadeesan, Jacob Thomas (2015) Imatinib-induced Extensive Hyperpigmentation in a Case of Chronic Myeloid Leukemia, Indian J Dermatol. Sep-Oct 60: 523 .

20Di Tullio F, Mandel VD, Scotti R, Padalino C, Pellacani G. (2018) Imatinib-induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature.57:784-790.